Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring
The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Limited sensitivity and limited target organ specificity are the major drawbacks for most peripheral clinical pathology parameters traditionally used for monitoring organ integrity both during preclinical toxicological assessment and clinical safety testing of investigational drugs. Several novel toxicity biomarkers have emerged as sensitive tools for detection, monitoring, quantification and prediction of solid organ toxicity. These tissue-specific, non-invasive biomarkers may provide valuable information for decision making during toxicological assessment and may be used for sensitive and specific target organ monitoring during clinical trials. This review critically discusses the opportunities and limitations of these biomarkers with respect to their translation into (first-in-human) clinical trials. A comprehensive overview is provided on serum- and urine-based biomarkers for hepatotoxicity, nephrotoxicity, cardiotoxicity, gonadotoxicity, pancreatic toxicity, vascular toxicity and phospholipidosis including species-specific assay availabilities and sampling regimens. In addition, the current regulatory status is presented and discussed in view of recent changes in regulatory acceptance by health authorities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the potential of the 3D hLiMT to report on the release of novel translational in vivo liver hepatotoxicity biomarkers, miR-122, a highly liver specific microRNA (Wang et al. 2009), HMGB1, a marker of immune modulation and necrosis (Antoine et al. 2009), and α-GST, a sensitive, highly specific and early biomarker for hepatocellular injury (Muller and Dieterle 2009), following exposure”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Muller and Dieterle 2009
Citations
Cites
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Mishra, J., Dent, C., Tarabishi, R., Mitsnefes, M. M., Ma, Q., Kelly, C., Ruff, S. M., Zahedi, K., Shao, M., Bean, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)74811-x · Cited by 2,394
Liver enzyme alteration: a guide for clinicians
Giannini, E. G. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040752 · Cited by 2,016
Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury
Han, W. K., Bailly, V., Abichandani, R., Thadhani, R., & Bonventre, J. V. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00433.x · Cited by 1,929
Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis
Dharnidharka, V. R., Kwon, C., & Stevens, G. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.34487 · Cited by 1,663
The current state of serum biomarkers of hepatotoxicity
Ozer, J., Ratner, M., Shaw, M., Bailey, W., & Schomaker, S. (2008) · Toxicology · doi:10.1016/j.tox.2007.11.021 · Cited by 1,269
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Viswanathan, C. T., Bansal, S., Booth, B., DeStefano, A. J., Rose, M. J., Sailstad, J., Shah, V. P., Skelly, J. P., Swann, P. G., & Weiner, R. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9291-7 · Cited by 826
Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement
Lee, J. W., Devanarayan, V., Barrett, Y. C., Weiner, R., Allinson, J., Fountain, S., Keller, S., Weinryb, I., Green, M., Duan, L., et al. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-9045-3 · Cited by 768
Urine NGAL Predicts Severity of Acute Kidney Injury After Cardiac Surgery: A Prospective Study
Bennett, M., Dent, C. L., Ma, Q., Dastrala, S., Grenier, F., Workman, R., Syed, H., Ali, S., Barasch, J., & Devarajan, P. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010907 · Cited by 765
Research works printed but not linked: 4
- Dieterle, 2008, Curr Opin Drug Discov Dev, 11, 60
- Bosch, 1995, Semin Nephrol, 15, 381
- Urbanova, 2006, Neoplasma, 53, 183
- Reisler, 2005, J Acquir Immune Defic Syndr, 39, 159
Cited by
The determination and interpretation of the therapeutic index in drug development
Muller, P. Y., & Milton, M. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3801 · Cited by 563
Self-citationUtility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
“2009), and α-GST, a sensitive, highly specific and early biomarker for hepatocellular injury (Muller and Dieterle 2009), following exposure to DILI positive drugs demonstrated in principle that this 3D liver model has the potential to recapitulate in vivo findings in vitro (Fig.”
BackgroundLiver Microphysiological Systems for Predicting and Evaluating Drug Effects
Ribeiro, A. J. S., Yang, X., Patel, V. P., Madabushi, R., & Strauss, D. G. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1458 · Cited by 127
The current status of biomarkers for predicting toxicity
Campion, S., Aubrecht, J., Boekelheide, K., Brewster, D. W., Vaidya, V. S., Anderson, L., Burt, D., Dere, E., Hwang, K., Pacheco, S., et al. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.827170 · Cited by 97
Translational biomarkers of acetaminophen-induced acute liver injury
Beger, R. D., Bhattacharyya, S., Yang, X., Gill, P. S., Schnackenberg, L. K., Sun, J., & James, L. P. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1519-4 · Cited by 92
Metadata
- Authors
- Muller, P. Y., & Dieterle, F.
- Affiliations
- Novartis (Switzerland) (CH)
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2009-07-17
- Volume
- 5
- Issue
- 9
- Pages
- 1023-1038
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2092612655
- Cited by
- 62
- References
- 81
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2022: 3 · 2021: 1 · 2019: 3 · 2018: 1 · 2017: 4 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 12 · 2012: 9
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Metabolism & Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- biomarkers of toxicity, tissue-specific biomarkers, non-invasive biomarkers, pharmacovigilance, preclinical toxicology, clinical trials, hepatotoxicity, nephrotoxicity, cardiotoxicity, gonadotoxicity, pancreatic toxicity, vascular toxicity, phospholipidosis, serum biomarkers, urinary biomarkers, regulatory acceptance
- MeSH terms
- Animals, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Biomarkers, Drug Approval, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. https://app.cochat.ai/papers/10.1517/17425250903114174
- The paper
- Muller, P. Y., & Dieterle, F. (2009). Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425250903114174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.